Melanoma and skin cancer trials can require specialised sites, carefully defined study populations and close coordination between oncology, dermatology, pathology, imaging and safety teams. The treatment landscape has also evolved considerably, with immunotherapies, targeted treatments and biomarker-led approaches introducing new opportunities alongside greater operational complexity.
PHARMExcel provides flexible CRO support for melanoma and skin cancer clinical trials, working with pharmaceutical, biotechnology, academic and research-led sponsors. Our teams support studies from feasibility and set-up through active delivery, data management and close-out.
As a smaller specialist CRO, we work closely with sponsor teams and adapt our involvement to the operational and scientific requirements of each study.
Clinical trial support for melanoma and skin cancer research
Melanoma develops from melanocytes and differs significantly from more common non-melanoma skin cancers such as basal cell carcinoma and squamous cell carcinoma. These differences affect treatment pathways, study populations, endpoints and the research centres best placed to deliver a trial.
Melanoma research increasingly includes immunotherapies, targeted treatments and combination approaches. Skin cancer research can also involve surgery, radiotherapy and local or systemic treatments depending on the cancer type, stage and objectives of the study.
PHARMExcel focuses on the clinical trial stage, helping sponsors turn the protocol into a practical delivery plan that reflects the disease setting, patient pathway and requirements of participating sites.
Feasibility and specialist site strategy
Site selection can have a significant influence on melanoma trial performance. Experienced oncology centres may already be involved in competing studies, while individual protocols can require narrowly defined populations, specialist investigators or specific clinical infrastructure.
PHARMExcel uses feasibility and site intelligence to assess patient availability, investigator experience, competing studies, site capacity and anticipated enrolment. Our knowledge of NHS, academic and specialist research environments is particularly valuable across the UK and Europe, where referral pathways can affect access to eligible participants.
These assessments help sponsors distinguish between sites that have general melanoma experience and those that are realistically equipped to deliver the individual protocol.
PHARMExcel does not directly recruit participants. Our role is to support recruitment feasibility and provide governance and oversight around site-led enrolment.
Biomarker-driven melanoma studies
Molecular characteristics play an increasingly important role in melanoma research. Biomarker-defined eligibility can reduce the available study population and introduce additional operational requirements around testing, sample handling, turnaround times and treatment decisions.
Studies may include participants selected according to BRAF mutation status or other molecular and clinical criteria relevant to the investigational treatment. These requirements need to be considered early because they can influence feasibility, site selection and screening pathways.
PHARMExcel can incorporate biomarker requirements into study planning and identify centres with appropriate clinical pathways and access to the required testing infrastructure.
Laboratory testing and molecular analysis remain the responsibility of qualified sites or specialist providers. PHARMExcel provides clinical trial coordination and oversight around these activities rather than performing testing directly.
Immunotherapy, targeted treatments and complex study designs
Melanoma has become an important area of research for immunotherapies, targeted treatments and combination strategies. Clinical trials continue to explore new agents, different treatment sequences and approaches designed to improve response or address treatment resistance.
These protocols can create operational challenges beyond standard study delivery. Eligibility criteria may be highly selective, treatment schedules can be demanding and studies may require close coordination between investigators, safety teams, medical monitors and data functions.
Earlier-phase oncology studies may also involve dose escalation, dose optimisation or multiple cohorts, creating a need for timely data review and clear communication between study functions.
PHARMExcel brings these disciplines together within the agreed study scope so that clinical, operational and safety considerations remain aligned as the trial progresses.
Safety and medical oversight
The safety profile of melanoma treatments can require structured assessment throughout a clinical trial, particularly when novel treatments or combination regimens are being investigated.
PHARMExcel provides pre-marketing pharmacovigilance and clinical trial safety support according to the risk profile of the investigational treatment and participant population. Services can include adverse event and serious adverse event processing, medical review, SUSAR management, safety monitoring plans and expedited reporting where required.
Medical monitoring provides additional clinical input into medically significant events, protocol-related questions and emerging safety information.
Independent safety monitoring committees can also be supported when required, including committee set-up, charter management, meetings and reporting.
Monitoring, data quality and melanoma study endpoints
Melanoma and skin cancer studies can generate information from several clinical sources, including tumour assessments, imaging, pathology, treatment records, safety findings and participant-reported outcomes.
PHARMExcel’s clinical monitoring teams work with investigator sites to maintain oversight of protocol compliance, source documentation, safety reporting and essential study records. Clinical data management and biostatistics can be integrated with monitoring activities to support query resolution, database preparation and statistical analysis.
The endpoints themselves vary considerably according to disease stage and treatment setting. Trials may assess tumour response, disease progression, recurrence, survival, safety or quality of life, while some studies require extended follow-up to understand the durability of treatment outcomes.
Advanced melanoma can also involve disease at different anatomical sites, including the brain, which may introduce additional imaging and assessment requirements.
Imaging, pathology review and other specialist procedures remain site or provider-led. PHARMExcel ensures that the associated requirements are incorporated appropriately into trial delivery and data oversight.
Melanoma and skin cancer study populations
Clinical research in this area can cover a range of disease settings, including:
- Cutaneous melanoma
- Advanced and metastatic melanoma
- Adjuvant melanoma studies
- Neoadjuvant melanoma studies
- Uveal melanoma
- Basal cell carcinoma
- Squamous cell carcinoma
- Other rare or specialist skin cancers
The operational requirements can differ considerably between these populations. A biomarker-selected metastatic melanoma study at specialist oncology centres, for example, presents different site and feasibility challenges from many non-melanoma skin cancer studies.
Understanding those differences early allows the operational model to reflect the actual disease setting rather than treating skin cancer as a single research category.
Why sponsors choose PHARMExcel for melanoma and skin cancer trials
PHARMExcel combines more than 15 years of clinical research experience with the flexibility of a smaller specialist CRO.
Our structure gives sponsors direct access to experienced professionals and reduces the number of organisational layers between the sponsor and study team. Project and study managers can remain involved as programmes progress from feasibility and set-up into active delivery, helping retain knowledge of the protocol, sites and earlier planning decisions.
Our experience spans commercial and academic-led clinical research, with particularly strong knowledge of NHS and specialist research environments in the UK alongside wider European site intelligence.
PHARMExcel operates an ISO 9001-certified quality management approach and has also been recognised as a Top 10 Oncology Solutions Provider 2025.
Sponsors can use PHARMExcel for a defined area of support or combine several functions into a broader clinical trial delivery model, depending on their internal capabilities and the requirements of the study.
Integrated CRO services for melanoma and skin cancer trials
PHARMExcel can support applicable studies through:
- Study feasibility and site selection
- Study start-up
- Clinical trial project management
- Clinical monitoring
- Trial-specific regulatory affairs
- Pre-marketing pharmacovigilance and safety management
- Medical monitoring
- Clinical writing
- Clinical data management
- Biostatistics
The service model can be built around the sponsor’s existing team rather than requiring every clinical research function to be outsourced.
Melanoma and skin cancer CRO FAQs
What does a melanoma CRO do?
A melanoma CRO supports the planning and delivery of clinical trials involving melanoma treatments.
Its role can include feasibility, specialist site selection, project management, regulatory support, monitoring, safety management, medical oversight, data management and statistics. The precise responsibilities depend on the protocol, treatment, study phase and capabilities already available within the sponsor’s team.
What makes melanoma trial feasibility particularly challenging?
Suitable participants may be concentrated within specialist centres, while competing oncology trials can reduce the population available to an individual study.
Biomarker requirements, treatment history, disease stage, referral pathways and site infrastructure can narrow the pool further. Effective feasibility therefore needs to evaluate the specific protocol rather than rely on general melanoma patient numbers.
How do biomarker requirements affect melanoma site selection?
Biomarker-defined studies need sites that can identify potentially eligible participants and support the required testing within study timelines.
Site assessment may therefore need to consider access to molecular testing, sample pathways, turnaround times and how biomarker results fit into screening and treatment decisions. PHARMExcel incorporates these factors into feasibility and operational planning.
Does PHARMExcel recruit participants for melanoma trials?
PHARMExcel does not directly recruit participants.
Our teams assess recruitment feasibility, support identification of suitable investigator sites and provide governance and oversight around site-led enrolment. This helps sponsors base enrolment assumptions on patient availability, referral pathways, competing research and actual site capacity.
How do melanoma and non-melanoma skin cancer trials differ?
Melanoma and non-melanoma skin cancers can have very different clinical pathways, treatments and research settings.
Advanced melanoma studies may involve systemic therapy, biomarker selection and specialist oncology centres, while research in basal or squamous cell carcinoma can involve different populations, endpoints and treatment approaches. Trial planning should reflect the specific cancer being studied.
Can PHARMExcel support uveal melanoma studies?
Uveal melanoma is a rare and clinically distinct melanoma with different patient pathways from the more common cutaneous form.
PHARMExcel can assess the feasibility, specialist site requirements and operational considerations of applicable studies, helping sponsors determine whether centres have appropriate investigator expertise, patient access and trial delivery capabilities.